Please login to the form below

I have forgotten my password

Spirogen

This page shows the latest Spirogen news and features for those working in and with pharma, biotech and healthcare.

MedImmune partners with US National Cancer Institute

AZ boosted its pipeline in thsi area with the $440m acquisition of Spirogen.

Latest news

MedImmune partners with US National Cancer Institute

AZ boosted its pipeline in thsi area with the $440m acquisition of Spirogen.
MPs grill Read over Pfizer's commitments to UK

with a move away from commercial-led megamergers and a shift towards small- and mid-scale, science-led acquisitions such as its recent purchase of Spirogen.
Soriot says pipeline will speed recovery at AZ

Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.
2013 - biotech boomed

AZ's 2013 deal-making spree also saw it acquire Amplimmune, a Maryland, US-based biotech with a number of early-stage cancer projects, and UK firm Spirogen, which develops ... Financial details of the AlphaCore deal were not released, but AZ's
AZ said to be eyeing Forest takeover bid

Last month the company agreed to pay $440m to buy antibody-drug conjugate (ADC) specialist Spirogen, while in August it bought cancer company Amplimmune in a deal valued at up to

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Pharma deals during October 2013

Auven's portfolio of companies includes Resolvyx, Kiacta, Kolitan and Sprout Pharmaceuticals, as well as Spirogen and ADC Therapeutics. ... The Spirogen/Auven Therapeutics deal with MedImmune discussed above re-confirms that ADC technology is certainly
Deal Watch table for October 2013

730. Spirogen / MedImmune. Acquisition. ADC technology - oncology (lead asset in phase II).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager – Med Comms – Kent: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Scientific Director: Great salary and bebefits

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Medical Writer, e-learning/ training, London: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer: Great salary and bebefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager – Med Comms – London: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Medical Writer - (London, Brighton or Copenhagen): Competitive

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer: Great salary and benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...